- In August 2022, Mycovia Pharmaceuticals, Inc. presented topline results from two studies on VIVJOA (Oteseconazole) capsules for recurrent vulvovaginal candidiasis (RVVC). The studies evaluated the drug’s effectiveness and safety in treating RVVC, showing promising results for a new therapeutic option for patients with this persistent and difficult-to-treat condition
- In August 2022, VIVJOA (Oteseconazole), an oral antifungal drug developed by Mycovia Pharmaceuticals, received FDA approval. This drug selectively inhibits fungal CYP5, marking a significant advancement in treating recurrent vulvovaginal candidiasis (RVVC). It offers a new treatment option for women suffering from this chronic condition, helping address the unmet medical needs of patients
- In June 2021, Scynexis, Inc. announced that their novel antifungal drug, BREXAFEMME (Ibrexafungerp), received FDA approval for treating vulvovaginal candidiasis (VVC). This oral treatment provides a new option for managing VVC, offering a distinct mechanism of action compared to other therapies. The approval highlighted Scynexis’s commitment to addressing unmet needs in women’s health
